BRIEF-Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion With FDA

Replimune

Replimune

REPL

0.00

May 29 (Reuters) - Replimune Group Inc REPL.O:

  • ANNOUNCES PLANNED RP1 BLA RESUBMISSION FOLLOWING PRODUCTIVE DISCUSSION WITH FDA

  • TO RESUBMIT RP1 BLA; FDA TO PRIORITIZE REVIEW AS URGENT

  • TO RESUBMIT RP1 BLA FOR ADVANCED MELANOMA AFTER ALIGNMENT WITH FDA

Source text: ID:nGNX7Bsnfr

Further company coverage: REPL.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.